Bethany J. Cavanagh - 22 Jan 2026 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role: SVP, Finance and Treasurer
Signature: By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol: BEAM
Transactions as of: 22 Jan 2026
Net transactions value: -$216,933
Form type: 4
Filing time: 26 Jan 2026, 16:05:05 UTC
Previous filing: 21 Jan 2026
Next filing: 02 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cavanagh Bethany J	SVP, Finance and Treasurer	C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE	By: /s/ Christine Bellon, Attorney-in-fact	26 Jan 2026	0002033155

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BEAM	Common Stock	Sale	$216,933	-6,198	-15%	$35.00	34,813	22 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.00 to $35.015, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.00 to $35.015, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.